New drug shows promise against superbug Staphylococcus aureus

1 min read

In a significant breakthrough, researchers Tharmalingam N et al. have discovered that Candesartan cilexetil (CC) exhibits potent anti-MRSA activity by disrupting the membrane of MRSA cells. This finding is particularly noteworthy as treatment options for MRSA are limited due to its multi-drug resistance.

The mechanism by which CC disrupts membrane homeostasis involves binding to bilayer lipid molecules, decreasing membrane fluidity, and down-regulating cell membrane and cell wall related genes and metabolites. Furthermore, the reduction of C20 fatty acids (C20:0) is found to confer CC-resistance, a state that can be reversed by supplementation with C20:0.

Structural activity relationship analysis reveals that the tetrazole ring and ester carbonic acid of CC are critical for antibacterial activity. This suggests that specific structural features of CC contribute to its ability to target MRSA membranes. The researchers' findings also demonstrate that CC potentiates the activity of aminoglycoside antibiotics, providing a potential new approach to treating MRSA infections.

As we reflect on this discovery, we are reminded of the intricate complexities of bacterial membranes and the importance of understanding their dynamics in order to develop effective treatments. The fact that CC can disrupt membrane homeostasis highlights the need for continued research into novel antimicrobial compounds and strategies to combat antibiotic resistance.

1 min read

In a world where antibiotic resistance threatens to undo centuries of medical progress, scientists have made a breakthrough that offers new hope. Researchers at Nature Communications have discovered that the anti-hypertensive drug Candesartan cilexetil can disrupt the membrane of methicillin-resistant Staphylococcus aureus (MRSA) cells. This finding has significant implications for the treatment of MRSA infections, a leading cause of bacterial infections worldwide.

The mechanism by which CC exerts its effects is multifaceted. It binds to bilayer lipid molecules and decreases membrane fluidity, down-regulating cell membrane and cell wall-related genes and related metabolites. Furthermore, it reduces C20 fatty acids, a key component that confers resistance to CC. This reduction in C20 fatty acids can be reversed by supplementation with the same fatty acid.

The researchers' findings suggest that CC has potential as a lead antimicrobial compound or potentiator against MRSA. The drug's ability to disrupt membrane homeostasis and potentiate the activity of gentamicin and polymyxin B antibiotics offers new avenues for treating MRSA infections. This breakthrough highlights the importance of continuing research into novel antimicrobial agents, which could ultimately save countless lives by combating the growing threat of antibiotic resistance.

1 min read

In the fight against some of the toughest infections known to humans, scientists have been searching for a new way to tackle a particularly stubborn foe: MRSA. This bacteria is the main cause of many serious illnesses, but doctors are struggling because it has developed resistance to most medicines. Recently, researchers found that an old medicine called Candesartan cilexetil might be just what they need to turn the tide.

When scientists looked at how Candesartan works, they discovered that its unique shape allows it to fit into the membrane of MRSA cells like a key fits into a lock. This makes the membrane more permeable and vulnerable to attack by other medicines. It's like adding a special kind of fuel to a car - when the bacteria can't make the membrane fluid enough, their inner workings start to break down. The researchers think that this new understanding could lead to a powerful tool against MRSA, one that might just save countless lives.